SMITHS GROUP SERVICES CORPORATION for SMITHS GROUP SERVICES CORPORATION
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Environment/Superfund ENV
Issues related to climate change and emissions technologies. Issues related to mechanical seals emissions technologies and energy infrastructure. Issues related to PFAS.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Torts TOR
General issues related to tort reform and minimal diversity jurisdiction. Civil liability issues in possible COVID related legislation.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Trade (domestic/foreign) TRD
General trade discussions including Section 301 and Section 232 tariffs. Issues related to the United States-Mexico-Canada Agreement (P.L.116-113).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Defense DEF
Issues related to CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) technology, detection solutions for the Department of Defense, and Navy RDT&E and Ship Equipment; H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021 and FY20/FY21 Department of Defense Appropriations.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
| KEVIN SCHMIDT | — |
Budget/Appropriations BUD
Funding for aviation security and homeland security technologies. H.R.1171, Funding for Aviation Screeners and Threat Elimination Restoration Act (FASTER Act); aviation security fees. Monitored applicable FY20 appropriations bills. FY21 Department of Homeland Security Appropriations; Transportation Security Administration (TSA) funding. FY21 Department of Defense Appropriations; Chemical Bio Funding; Navy RDT&E. FY21 Commerce, Justice, Science Appropriations; Opioid Funding. FY21 Departments of Labor, Health and Human Services, and Education Appropriations; Reimbursement for Medical Devices.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
| KEVIN SCHMIDT | — |
Aviation/Airlines/Airports AVI
Aviation security solutions and detection technologies for the Transportation Security Administration (TSA). FY20/FY21 DHS Authorization. Aviation security fees; H.R.1171, Funding for Aviation Screeners and Threat Elimination Restoration Act (FASTER Act).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN SCHMIDT | — |
Homeland Security HOM
Issues related to aviation security solutions and detection technologies for the Transportation Security Administration (TSA), Department of Homeland Security (DHS), U.S. Customs and Border Protection (CBP) and the Domestic Nuclear Detection Office (DNDO). Issues related to CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) technology and other border security solutions. TSA funding and aviation security fees generally. FY20/FY21 Department of Homeland Security Appropriations. Implementation of SUPPORT for Patients and Communities Act (P.L.115-271), law enforcement grants.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN SCHMIDT | — |
Medical/Disease Research/Clinical Labs MED
Issues related to patient infusion therapy, Medicare reimbursements for tracheotomy tubes, reimbursement/policy issues related to opioid alternative treatments, and medical device technology related to the opioid epidemic. Implementation of the 21st Century Cures Act (P.L.114-255). Implementation of Medicare Part B Home Infusion Services Temporary Transitional Payment Act. H.R.5172/S.3067, NOPAIN Act. Federal COVID response, including Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L.116-136).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.